Suzhou Hokapi Biomedical Engineering Co. Ltd. is co-founded by Suzhou Institute of Biomedical Engineering and Technology, Changchun Institute of Optics and Fine Mechanics and Physics, and natural person shareholder in 2009.
We are a high-tech enterprise focusing on R&D, manufacturing and sales of IVD products in China and worldwide. Our main products include automatic chemiluminescence immunoassay (CLIA) system and automatic blood grouping analyzers. We are dedicated to provide with high-quality IVD products for clinical diagnosis.
In November 2018, bioMérieux acquired a majority shareholding in Suzhou Hokapi Biomedical Engineering Co., Ltd and increased controlling share to 92.56% by October 2023. With this acquisition, HOKAPI has formed a strong team of professionals specialized in clinical laboratory instruments and IVD reagents to address healthcare needs.
37,068 M2(3.73Ha)
Land Area
72,142 M2
Building Size
2M Kits
Reagent MFG Capacity(2 Floors)
474M
Total Investment Budget
2,500 Units
Instrument MFGCapacity (2 Floors)
The new site was completed and bioMérieux R & D and Innovation Incubation Center (Suzhou) was inaugurated.
TLA AF-8000 has been approved by NMPA.
Desk CLIA AE-200 has been approved by NMPA, and obtained EU IVDR certification.
The second wave of 36 reagents obtained EU IVDR certification.
High throughput CLIA AE-480Plus has been approved by NMPA.
Hs Troponin I & IL-6 have been approved by NMPA and been launched on the market.
The first wave of 13 reagents obtained EU IVDR certification.
HOKAPI-China office
Contact: International Business Department
Email: market@hokapi.com service@hokapi.com
Please tell us your request using the form under "CONTACT US"
